Current and historical daily PE Ratio for Synaptogenix Inc (
) from 2020 to Jun 05 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Synaptogenix stock (SNPX) PE ratio as of Jun 05 2024 is 0.
More Details
Synaptogenix Inc (SNPX) PE Ratio (TTM) Chart
Synaptogenix Inc (SNPX) PE Ratio (TTM) Historical Data
View and export this data going back to 2020. Start your Free Trial
Total 877
- 1
- 2
- 3
- 4
- 5
- 6
- 10
| Synaptogenix PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-05 | At Loss | 2024-04-02 | At Loss |
| 2024-06-04 | At Loss | 2024-04-01 | At Loss |
| 2024-06-03 | At Loss | 2024-03-28 | At Loss |
| 2024-05-31 | At Loss | 2024-03-27 | At Loss |
| 2024-05-30 | At Loss | 2024-03-26 | At Loss |
| 2024-05-29 | At Loss | 2024-03-25 | At Loss |
| 2024-05-28 | At Loss | 2024-03-22 | At Loss |
| 2024-05-24 | At Loss | 2024-03-21 | At Loss |
| 2024-05-23 | At Loss | 2024-03-20 | At Loss |
| 2024-05-22 | At Loss | 2024-03-19 | At Loss |
| 2024-05-21 | At Loss | 2024-03-18 | At Loss |
| 2024-05-20 | At Loss | 2024-03-15 | At Loss |
| 2024-05-17 | At Loss | 2024-03-14 | At Loss |
| 2024-05-16 | At Loss | 2024-03-13 | At Loss |
| 2024-05-15 | At Loss | 2024-03-12 | At Loss |
| 2024-05-14 | At Loss | 2024-03-11 | At Loss |
| 2024-05-13 | At Loss | 2024-03-08 | At Loss |
| 2024-05-10 | At Loss | 2024-03-07 | At Loss |
| 2024-05-09 | At Loss | 2024-03-06 | At Loss |
| 2024-05-08 | At Loss | 2024-03-05 | At Loss |
| 2024-05-07 | At Loss | 2024-03-04 | At Loss |
| 2024-05-06 | At Loss | 2024-03-01 | At Loss |
| 2024-05-03 | At Loss | 2024-02-29 | At Loss |
| 2024-05-02 | At Loss | 2024-02-28 | At Loss |
| 2024-05-01 | At Loss | 2024-02-27 | At Loss |
| 2024-04-30 | At Loss | 2024-02-26 | At Loss |
| 2024-04-29 | At Loss | 2024-02-23 | At Loss |
| 2024-04-26 | At Loss | 2024-02-22 | At Loss |
| 2024-04-25 | At Loss | 2024-02-21 | At Loss |
| 2024-04-24 | At Loss | 2024-02-20 | At Loss |
| 2024-04-23 | At Loss | 2024-02-16 | At Loss |
| 2024-04-22 | At Loss | 2024-02-15 | At Loss |
| 2024-04-19 | At Loss | 2024-02-14 | At Loss |
| 2024-04-18 | At Loss | 2024-02-13 | At Loss |
| 2024-04-17 | At Loss | 2024-02-12 | At Loss |
| 2024-04-16 | At Loss | 2024-02-09 | At Loss |
| 2024-04-15 | At Loss | 2024-02-08 | At Loss |
| 2024-04-12 | At Loss | 2024-02-07 | At Loss |
| 2024-04-11 | At Loss | 2024-02-06 | At Loss |
| 2024-04-10 | At Loss | 2024-02-05 | At Loss |
| 2024-04-09 | At Loss | 2024-02-02 | At Loss |
| 2024-04-08 | At Loss | 2024-02-01 | At Loss |
| 2024-04-05 | At Loss | 2024-01-31 | At Loss |
| 2024-04-04 | At Loss | 2024-01-30 | At Loss |
| 2024-04-03 | At Loss | 2024-01-29 | At Loss |
Synaptogenix Inc (SNPX) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Synaptogenix Inc
NAICS : 541714
SIC : 2833
ISIN : US87167T2015
Share Class Description:
SNPX: Ordinary SharesDescription
Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers